Articles

How an Injectable Became a Significant Tool In Bone Health

Pam Skurkay talks about when she and other nurses began using a medicine to treat bone-related health issues and how they eventually allowed outside medical offices the pre-authorization to use it. Read More ›

Decreasing Skeletal Issues

By Pam Skurkay, RN, BSN, CPAN, CURN; Dianna Shafer, BSN, CURN, CPN, CPC-I; Angela Hunter, BSN

Genitourinary Cancers, Video

TON Interview with the Innovators: Volume 1

Dianna Shafer and Angela Hunter talk about the DEXA scan results, and how the implementation of a specific therapy helped decrease bone-related issues. Read More ›

Bone Health and Prostate Cancer

By Pam Skurkay, RN, BSN, CPAN, CURN; Dianna Shafer, BSN, CURN, CPN, CPC-I; Angela Hunter, BSN

Genitourinary Cancers, Video

TON Interview with the Innovators: Volume 1

Dianna Shafer talks about how bone health goes with prostate health treatment, and trying to avoid skeletal health events. Read More ›

Immunotherapy and DEXA Scans

By Pam Skurkay, RN, BSN, CPAN, CURN; Dianna Shafer, BSN, CURN, CPN, CPC-I; Angela Hunter, BSN

Genitourinary Cancers, Video

TON Interview with the Innovators: Volume 1

Pam Skurkay, Dianna Shafer, and Angela Hunter discuss the positive scan results they are seeing post-immunotherapy when using denosumab. Read More ›

Venclexta FDA Approved for Patients with CLL

FDA Updates, In the News

Web Exclusives

Venetoclax (Venclexta) has been approved by the US Food and Drug Administration (FDA) for daily use in patients with chronic lymphocytic leukemia (CLL) who have 17p deletion, and had ≥1 prior therapies, according to an announcement by the agency. This drug is the first treatment that targets the B-cell lymphoma 2 protein, which is overexpressed in many patients with CLL. Read More ›

FDA Approves Defitelio for Patients with Rare Disorder After HSCT

FDA Updates, In the News

Web Exclusives

Defibrotide sodium (Defitelio) is now US Food and Drug Administration (FDA)-approved for children and adult patients with hepatic veno-occlusive disease (VOD) with added kidney or lung abnormalities following hematopoietic stem cell transplantation (HSCT). This drug is the first to be approved for patients with severe hepatic VOD. Read More ›

FDA Enhances Warnings for Serious Risks of Opioid Analgesics Abuse

FDA Updates, In the News

Web Exclusives

Immediate-release opioid analgesics will now require boxed warnings regarding the serious risks for abuse, addiction, overdose, neonatal opioid withdrawal syndrome (NOWS), and death associated with the drugs, according to an announcement by the US Food and Drug Administration (FDA). Read More ›

Providing Care for the Whole Patient: Sexuality and Cancer

Survivorship

TON March 2016 Vol 9 No 2

The Oncology Nurse-APN/PA spoke with Anne Katz, PhD, RN, FAAN, about her chosen career as a certified Sex Counselor at CancerCare Manitoba and Clinical Nurse Specialist at the Manitoba Prostate Centre in Canada. Read More ›

Acute Myeloid Leukemia: Understanding the Patient’s Experience

By Caroline Helwick

Hematologic Cancers

TON March 2016 Vol 9 No 2

Patients with acute myeloid leukemia (AML) often feel blindsided by their diagnosis, have trouble understanding their treatment choices, and suffer symptoms that are inadequately addressed. This is a patient population with sizable, and unmet, palliative care and psychosocial needs. Read More ›